Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Pacific Biosciences Deal Further Investigated by UK Authority

NEW YORK – The UK's Competition and Markets Authority (CMA) said yesterday that it is referring the proposed Illumina acquisition of Pacific Biosciences for an in-depth Phase 2 investigation to assess whether it might result in a substantial lessening of competition in the sequencing market.

The decision was widely expected after CMA said earlier this month that it would initiate a second-phase investigation unless the two companies adequately addressed its concerns about reduced competition.

In a note accompanying its decision, CMA said that on June 25, Illumina and PacBio "informed the CMA that they would not offer such undertakings to the CMA. Accordingly, the CMA has decided to make a reference." CMA's chair will now form a group to conduct the Phase 2 investigation.

Illumina said earlier this month that due to the expected further review by CMA, it now expects the deal to close in the fourth quarter.

Illumina announced plans to acquire PacBio for approximately $1.2 billion in cash in November 2018. The firm had previously expected to close the deal mid-2019.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.